Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. - Wikidata - awgldk - TriplyDB

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

http://www.wikidata.org/entity/Q34175100

about

Community acquired bacterial pneumonia Immunomodulation in sepsis: state of the art and future perspective Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis Preventing and treating secondary bacterial infections with antiviral agents Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Pneumococcal pneumonia: differences according to blood culture results.Community-acquired pneumonia in elderly patients.Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms.New modalities in treating pneumococcal pneumonia.Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Choosing the right combination therapy in severe community-acquired pneumonia The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.Lung inflammatory pattern and antibiotic treatment in pneumonia Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types.Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza Respiratory Infections in the U.S. Military: Recent Experience and Control Pneumolysin in the immunopathogenesis and treatment of pneumococcal disease.Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Azithromycin and lower respiratory tract infections.Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.Update on community-acquired pneumonia. New pathogens and new concepts in treatment.Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.Severe community-acquired pneumonia: approach to therapy.Controversies in the treatment of pneumococcal community-acquired pneumonia.Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.Novel targets in the management of pneumonia.Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice.Pneumonia in low and middle income countries: progress and challenges.Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic.Advances in the prevention, management, and treatment of community-acquired pneumonia Bacteraemic pneumococcal pneumonia: current therapeutic options.Emerging drugs for pneumococcal pneumonia.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Elderly patients with community-acquired pneumonia: optimal treatment strategies.Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review.

P2860

Q22241379-A157D1E3-A290-4266-B434-80C091F61382 Q22305766-5FA306D2-ADFD-43A6-A99B-97AF20B944E8 Q24655866-8E7148CB-2B1B-41FE-99C5-B25797AFA046 Q26747529-E4924C8E-96CA-4603-9EC3-2BA0476F713B Q30401260-E34355D7-F98F-40C7-98C1-9E7372E44A2E Q33572569-A5F7AD28-28B6-4F62-B901-C8F1B885A584 Q33790704-D1295427-6C23-41FB-89F6-75B73EC21B80 Q33943151-3244897F-AA06-4EAB-9E37-A8AC3E97300D Q33983140-C2057752-8778-4D8D-ACEA-8DF27940CE85 Q34021594-74A1985F-E3E9-4A2D-AC6E-2179B5669351 Q34048462-C1275C0C-F86A-40F9-83E0-7ACCDC6D38C5 Q34108527-E361BAA7-DA09-4261-A800-C4D978163F19 Q34185386-F4002C6F-0039-4E2F-920E-D70862135F50 Q34375192-1FA87D2C-F882-4273-8F7A-383E17234506 Q34999131-C01DB544-1493-4B3E-A1FD-574729E7D8BB Q34999299-4F6B2D8D-A7C7-4BAA-A31D-D6FC976A5369 Q35083508-F9F6BEB6-FEF6-4148-8C49-4722A46C9484 Q35199208-D10E98E2-619A-49C8-A993-B56A51F4E16A Q35557119-7707D64D-CC05-4ABC-B453-A20E503AFC2B Q35763405-D0E8DAB5-044E-4739-9F7C-1BF6C2D81DD7 Q35917193-7589E63C-1444-4E6B-A0E9-B0D0DABC1212 Q36072425-3FEBE9A2-85CE-4C42-9861-FC2D3378E136 Q36281234-BF78C91F-4508-4168-A30C-EF8ADE4278C2 Q36283753-1793F7D2-9AFE-463A-897B-90F4CD71FB02 Q36295507-C8DF3335-E885-4294-89E7-33D7C5F6C29E Q36316474-FCD1EF20-9A64-4111-8769-BD54E312F06C Q36634020-2B778EA3-39E2-460D-BE41-F86B4B6C4406 Q36765778-D36505B2-E796-4A7B-8D4F-8245F5AE02C8 Q36895630-AC6B9FD9-007E-4610-B54C-BAF9D7C3EDB5 Q37203889-6AAC884E-9601-4FC8-9BDF-B08B9AD464C0 Q37362652-3093A105-1743-47EF-85A0-05BDB20E5672 Q37607163-2B83E238-1FE7-41D3-A4D3-6686E3A01653 Q37650969-380801C3-7A13-4E09-B50E-D0FDB05AA231 Q37697321-59626B81-D8CA-4408-90A0-F30C529AB3E6 Q37822666-F2A1FB97-CA96-4E0E-A48B-42DCFC8FDD3D Q37833059-E70B82DB-0241-498F-A02C-DAB5F534DEC3 Q37864327-1836C705-0379-45A9-ADFF-3B3C7E270C89 Q37868241-AEAB1853-E3A8-474C-9512-49E9415D16B3 Q37896600-B17C7637-12FD-4018-8D5D-8C4B98109BA2 Q37970666-AB71B853-BF1D-47C6-9886-FED4066F846F

P2860

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

http://www.wikidata.org/entity/Q34175100

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@ast

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@en

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@nl

type

label

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@ast

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@en

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@nl

prefLabel

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@ast

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@en

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@nl

P1433

Q34175100-A937AEE5-E7D4-4D87-9805-3D7A33DBC93E

P1476

Q34175100-01413D44-7523-4BDD-BE52-03E8B7328106

P2093

Q34175100-1BE4A794-D626-4D0E-A195-6EA4606DAC31

Q34175100-28D0958C-A3F1-4023-9672-024537742753

Q34175100-5205FD44-9EE4-453C-9615-E8F453DA9B41

Q34175100-80EBBDF9-0053-4479-8D32-21081E59B2CF

Q34175100-AD0E4C8D-914B-4FCB-AA6B-F2B3F4E04F5E

Q34175100-E9487488-4728-484C-A7E1-CC736EE1CE4F

Q34175100-F366CE0D-DFE1-4840-8278-C3FAB43D006B

P304

Q34175100-E8A8FA1F-8B61-4D70-8A66-1A2D6D54F7CF

P31

Q34175100-8412D26D-7585-40AD-895F-4806AB8F98E5

P356

Q34175100-6E194846-867F-4023-B6D5-D765EE83B697

P407

Q34175100-2BAF0734-81A5-40F0-97DE-A1B9F2443EBB

P433

Q34175100-03182754-5A8B-4760-B53E-0FD08D207C8D

P478

Q34175100-B28170CD-37FE-4429-8D81-78F3543C31A3

P50

Q34175100-049AD494-3EA3-4BF4-A939-C5246A282501

Q34175100-0DBF1950-0364-4292-B2D7-73AF49876483

P577

Q34175100-5652CCD3-C2E7-4230-B497-B6422607AC8E

P5875

Q34175100-195B413F-B057-4A7E-B878-5031F91EC97C

P698

Q34175100-AB6EDCC5-C407-44A9-9077-5E816EC67AEA

P921

Q34175100-9F38DF11-4439-45B2-8C0D-0F1B7C555C74

Q34175100-EF1377A1-1000-4713-A4B8-752730D55CB3

P356

P1433

Clinical Infectious Diseases

P1476

Addition of a macrolide to a b ...... eremic pneumococcal pneumonia.

@en

P2093

Antoni Torres

http://www.w3.org/2001/XMLSchema#string

Elisa García

http://www.w3.org/2001/XMLSchema#string

Francesc Marco

http://www.w3.org/2001/XMLSchema#string

Josep Mensa

http://www.w3.org/2001/XMLSchema#string

José A Martínez

http://www.w3.org/2001/XMLSchema#string

Manuel Almela

http://www.w3.org/2001/XMLSchema#string

Maria Angeles Marco

http://www.w3.org/2001/XMLSchema#string

P304

389-395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/367541

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Juan Pablo Horcajada

P577

2003-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10918268

http://www.w3.org/2001/XMLSchema#string

P698

12567294

http://www.w3.org/2001/XMLSchema#string

P921